Eli Lilly pairs with GE to study cancer drugs

In a deal that further underscores the growing importance of diagnostics, GE and Eli Lilly have signed a three-year agreement to study the pharmacological effects of a wide range of cancer drugs and develop in vitro diagnostic tests based on their findings. The companies hope to create tests that predict cancer treatment response to targeted therapies so that physicians can make informed decisions about which targeted therapies will be the most effective for patients.

"The combination of diagnostics and therapeutics is opening new doors in the fight against cancer and other life-threatening diseases. Through the application of molecular and cell biology to understanding disease, we can provide pharmaceutical companies with more advanced tools to develop more optimal drug therapies for cancer patients," said Dr. Michael Montalto, head of Molecular Imaging and Diagnostics Advanced Technologies for Global Research.

- see this release for more

Related Articles:
Drug, diagnostic combos are the future. Report
Personalized medicine advances with new genetic test. Report
GE, Abbott call off $8.1B diagnostics deal. Report
GE negotiating for Abbott diagnostics unit. Report
JPMorgan, GE make healthcare acquisitions. Report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.